Platelet News and Research

RSS

Accumetrics secures $24 million in capital infusion

Accumetrics, Inc., a privately-held developer and marketer of the VerifyNow System, the first rapid and easy-to-use point-of-care system for measuring platelet reactivity to multiple antiplatelet agents, announced today that it has completed its capital financing efforts, the first round of which was announced in the Fall of 2009.

2 Sep 2010

J-LANCELOT trial finds E5555 may reduce MACE without increasing serious bleeding events

Aspirin and thienopyridine antiplatelet therapy (such as clopidogrel) are standard care in the treatment of acute coronary syndrome (ACS) and even in stable coronary artery disease (CAD) after coronary intervention with stent. However, effective antiplatelet agents are needed which do not increase the risk of bleeding.

31 Aug 2010

Antithrombotic therapy increases bleeding risk in CAD patients: Research

Antithrombotic therapy using antiplatelet and anticoagulant agents is the cornerstone of treatment for acute and chronic coronary artery disease (CAD), yet it is also associated with an increased risk of bleeding. It is paradoxical that elderly patients, the most likely population to develop CAD, are those that suffer most from bleeding complications.

31 Aug 2010

Phase 2 INNOVATE PCI trial results for elinogrel presented

Phase 2 trial results for elinogrel, a novel antiplatelet agent available in both intravenous and oral formulations, were presented here today.

30 Aug 2010

Jefferson scientists receive grant to study genetics of platelet gene expression

Scientists at Jefferson Medical College have received a four-year, $3 million National Institutes of Health grant funded by the National Heart, Lung and Blood Institute to study variations of platelet function, specifically, the genetics of platelet gene expression. The study aims to find data that can be translated into novel therapeutic strategies and develop better predictors of cardiovascular disease.

30 Aug 2010

Study finds BMI, thrombogenic factor increases cardiovascular risk

Although having a high body mass index (BMI) is a known risk factor for cardiovascular disease, researchers are only beginning to understand how BMI affects the physiological processes involved in the development of the disease. Now, a study of a subset of women in the Kronos Early Estrogen Prevention Study (KEEPS), suggests that as BMI increases, so do platelet reactivity and thrombogenic microvesicles and activated protein C in the blood-all of which contribute to the formation of atherothrombosis and associated cardiovascular events.

30 Aug 2010

FDA grants LFB's recombinant anti-CD20 monoclonal antibody orphan drug status for CLL

The recombinant anti-CD20 monoclonal antibody produced by LFB Biotechnologies received orphan drug status for the treatment of Chronic Lymphocytic Leukemia (CLL). This approval from the FDA Office of Orphan Products Development was granted on August 6th, 2010.

26 Aug 2010

Cerus to acquire BioOne's commercialization rights for INTERCEPT Blood System

Cerus Corporation announced today that it has signed an agreement to acquire BioOne Corporation's commercialization rights for the INTERCEPT Blood System for platelets and plasma, subject to approval of the transaction by BioOne's shareholders. In 2004 and 2005, Cerus and its partner at the time, Baxter International, licensed the commercialization rights for INTERCEPT platelets and plasma to BioOne for an Asian territory, which included China, Japan, Taiwan, Singapore, Korea, Thailand and Vietnam.

25 Aug 2010

Genzyme announces publication of phase 2 clinical trial results of eliglustat tartrate for Gaucher disease

Genzyme Corporation announced today that the two-year follow-up results from the phase 2 clinical trial of its investigational therapy known as eliglustat tartrate have been accepted for publication in the journal Blood. The results have been pre-published on the journal's website and are available to subscribers.

23 Aug 2010

Stent implanted in artery inside skull of 14-year-old boy to prevent stroke

University at Buffalo neurosurgeon Elad Levy, MD, implanted a stent in an artery inside the skull of a 14-year-old boy to prevent a stroke, a procedure thought to be the first conducted in an adolescent.

20 Aug 2010

Bolder BioTechnology receives $600,000 NIH SBIR grant to study long-acting IL-11 analog in ARS

Bolder BioTechnology, Inc. today announced that it has been awarded a Phase I Small Business Innovation Research (SBIR) grant totaling $600,000 from the National Institute of Allergy and Infectious Diseases (NIAID) of The National Institutes of Health (NIH). The grant will be used to demonstrate the feasibility of using our novel, long-acting IL-11 analog to accelerate platelet recovery and improve survival in a mouse model of Acute Radiation Syndrome (ARS).

18 Aug 2010

Toshiba America Medical Systems/RSNA issues grant to three researchers

The Radiological Society of North America (RSNA) Research & Education (R&E) Foundation awarded 2010 Toshiba America Medical Systems/RSNA grants to Kenneth S. Lee, M.D., Nitin Ohri, M.D., and Ben Paxton, M.D. The grants are made possible by Toshiba's support of the RSNA R&E Foundation.

18 Aug 2010

CaridianBCT releases version 6.0 of Trima Accel Automated Blood Collection System

CaridianBCT, the leading global provider of technology, products and services in the blood banking, transfusion medicine and cell therapy industries, announced the global release of the Trima Accel® Automated Blood Collection System Version 6.0. The latest version of the flagship automated blood collection platform provides streamlined operations and potentially increased cost savings for customers worldwide.

18 Aug 2010

CD31 positive cells have potential for treating peripheral artery disease: Research

Isolating cells from a patient's blood or bone marrow that nourish blood vessels may be a safer and less arduous route to treatment of cardiovascular disease than obtaining rare stem cells, according to research from Emory University School of Medicine. In recent clinical trials, doctors in several countries have tested the ability of a patient's bone marrow cells to repair damage, such as heart attacks and peripheral artery disease, created by problems of blood flow.

16 Aug 2010

FDA grants new 510(k) clearance for Fenwal's Amicus blood cell separator

Fenwal Inc., a global medical technology company focused on improving blood collection, separation, safety and availability, announced today that the U.S. Food and Drug Administration has granted Fenwal a new 510(k) clearance for its Amicus® blood cell separator.

13 Aug 2010

FDA grants BioMimetic Therapeutics orphan drug designation for rhPDGF-BB in treatment of OCD

BioMimetic Therapeutics, Inc. today announced that it has received orphan drug designation from the Food and Drug Administration for its protein therapeutic, recombinant human platelet derived growth factor, to be used in conjunction with autograft and/or commercially available osteochondral allograft for the treatment of osteochondritis dissecans of the knee, elbow or ankle.

12 Aug 2010

IL releases new HemosIL HIT-Ab(PF4-H) assay

Instrumentation Laboratory (IL) today announced the release of the new HemosIL HIT-Ab(PF4-H) assay as a European CE IVD Mark product under the European Directive on In Vitro Diagnostic Medical Devices. Delivering results in minutes, the HemosIL HIT-Ab(PF4-H) assay detects total immunoglobulin against Platelet Factor 4-Heparin complexes, the antibodies associated with the pathology of HIT.

4 Aug 2010

Celera decreases second-quarter net loss to $6.1 million

Celera Corporation today reported net revenues of $32.6 million for the second quarter of 2010 that ended June 26, 2010, compared to $41.4 million for the prior year quarter. For the second quarter of 2010, Celera reported a net loss of $6.1 million, or $0.07 per share, compared to a net loss of $31.7 million, or $0.39 per share, for the prior year quarter.

4 Aug 2010

New findings on snake venom toxin hold promise for developing heart disease, cancer therapies

Researchers seeking to learn more about stroke by studying how the body responds to toxins in snake venom are this week releasing new findings that they hope will aid in the development of therapies for heart disease and, surprisingly, cancer. The Japanese team is reporting in a Journal of Biological Chemistry "Paper of the Week" that they are optimistic that inhibiting a protein found on the surface of blood cells known as platelets may combat both irregular blood clotting and the spread of certain cancers throughout the body.

30 Jul 2010

Sysmex America to debut expanded cell image analysis portfolio at AACC Annual Conference

Sysmex America, Inc., a leading medical diagnostic instrument manufacturer and information systems developer, today announced plans to debut its expanded cell image analysis portfolio during this year's American Association of Clinical Chemistry's (AACC) Annual Conference and Clinical Lab Expo July 25 - 29 in Anaheim, California.

From Sysmex America, Inc. 27 Jul 2010

Platelet News and Research

Accumetrics secures $24 million in capital infusion

J-LANCELOT trial finds E5555 may reduce MACE without increasing serious bleeding events

Antithrombotic therapy increases bleeding risk in CAD patients: Research

Phase 2 INNOVATE PCI trial results for elinogrel presented

Jefferson scientists receive grant to study genetics of platelet gene expression

Study finds BMI, thrombogenic factor increases cardiovascular risk

FDA grants LFB's recombinant anti-CD20 monoclonal antibody orphan drug status for CLL

Cerus to acquire BioOne's commercialization rights for INTERCEPT Blood System

Genzyme announces publication of phase 2 clinical trial results of eliglustat tartrate for Gaucher disease

Stent implanted in artery inside skull of 14-year-old boy to prevent stroke

Bolder BioTechnology receives $600,000 NIH SBIR grant to study long-acting IL-11 analog in ARS

Toshiba America Medical Systems/RSNA issues grant to three researchers

CaridianBCT releases version 6.0 of Trima Accel Automated Blood Collection System

CD31 positive cells have potential for treating peripheral artery disease: Research

FDA grants new 510(k) clearance for Fenwal's Amicus blood cell separator

FDA grants BioMimetic Therapeutics orphan drug designation for rhPDGF-BB in treatment of OCD

IL releases new HemosIL HIT-Ab(PF4-H) assay

Celera decreases second-quarter net loss to $6.1 million

New findings on snake venom toxin hold promise for developing heart disease, cancer therapies

Sysmex America to debut expanded cell image analysis portfolio at AACC Annual Conference

Event guide: 4th Extra-Hepatic Lipid-Based Nanoparticles Delivery Summit eBook

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News